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Polycystic Ovarian Syndrome (PCOS) is a complex disorder associated with various 
reproductive, metabolic and cardiovascular abnormalities and is present in 
approximately 15% of women of reproductive age. The hallmarks include androgen 
excess, ovulatory dysfunction and insulin resistance which is believed to play a role in 
the pathogenesis of the disorder.  Although the exact mechanisms of PCOS are 
unknown, intrinsic dysfunction of ovarian theca and granulosa cells are also thought 
to contribute to altered steroid production and follicle development which may 
explain the clinical features of the syndrome.  
Metformin, an insulin sensitising agent may improve both metabolic and 
reproductive aspects of the disorder, however, the development of new therapeutic 
agents for PCOS is still required.  Women with PCOS are inclined to seek 
complementary and alternative treatment options such as Chinese Herbal Medicine, 
warranting further investigation into the efficacy of the herbs commonly used. 
Paeoniflorin, the major compound of the herb, Radix Paeoniae Albus has 
demonstrated the ability to ameliorate insulin resistance in animal models, however 
the effects and mechanisms of paeoniflorin for the treatment of PCOS has yet to be 
elucidated.  
This study therefore used a dexamethasone-induced in vitro model of PCOS in 
murine theca and granulosa cells to determine the effects of paeoniflorin on 
secretion of key hormones testosterone, progesterone and oestradiol, cell 
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proliferation as well as the molecular mechanisms in which paeoniflorin may regulate 
steroid production.  Dexamethasone (10 μM) increased theca cell androgen 
production and adversely affected oestradiol: progesterone ratios in granulosa cells. 
Meanwhile, paeoniflorin (100 μg/mL) decreased androgen production in 
dexamethasone-induced theca cells and maintained normal oestradiol: progesterone 
ratios in granulosa cells.  In theca cells, this was shown to be through downregulation 
of cholesterol side-chain cleavage enzyme and 17,20-lyase protein expression. 
Paeoniflorin also increased mRNA gene expression of CYP11A1 which may indicate 
influence over transcription factors or post-translation modifiers, particularly in 
relation to cell differentiation.  
Together, these results suggest that firstly, dexamethasone can be considered a 
useful in vitro model of PCOS in murine ovarian cells. Secondly, paeoniflorin may be 
a novel agent for the treatment of PCOS by ameliorating hyperandrogenism and 
improving ovarian function. Further research into the effect of paeoniflorin in 
differentiation of theca cells as well as the molecular mechanisms in which 
paeoniflorin attenuates hormones in granulosa cells is needed. Finally, this research 
can potentially support future animal or clinical studies to further improve the 
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